Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387472908> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4387472908 endingPage "448" @default.
- W4387472908 startingPage "437" @default.
- W4387472908 abstract "Eosinophilic esophagitis (EoE) is a food allergen-induced disease of the esophagus. Chronic, eosinophil-predominant inflammation eventually leads to fibrosis, esophageal dysfunction and severe morbidity. Swallowed topical corticosteroids (STCs) are a mainstay of anti-inflammatory therapy in the treatment of active EoE. Data on the efficacy of novel corticosteroid formulations, developed specifically for esophageal delivery, have recently become available.A comprehensive review was performed aiming to summarize evidence on the role of STCs in the treatment of EoE. Two biomedical bibliographic databases (PubMED, EMBASE) were searched for articles providing original information on the efficacy and safety of STCs in adult EoE patients.Budesonide orodispersible tablet (BOT) and budesonide oral suspension (BOS) both surpassed placebo formulations regarding the efficacy of inducing and maintaining histologic, symptomatic and endoscopic remission. Overall, BOT displayed the highest grade of efficacy with clinico-histologic remission rates up to 75% after 1 year. Fluticasone propionate (APT-1011) achieved and maintained histologic and endoscopic responses in the majority of patients, whereas only a positive trend was demonstrated for symptomatic improvement. Mometasone and ciclesonide were studied in a limited number of smaller-scale trials and placebo-controlled data are required to substantiate the promising findings. All STCs displayed a similar side effects profile and were generally considered safe and well-tolerated.Current evidence supports long-term treatment with novel corticosteroid formulations, challenging the established treatment paradigm of EoE. BOT appears to be the most effective steroid therapy, although head-to-head comparative trials between STCs are needed." @default.
- W4387472908 created "2023-10-11" @default.
- W4387472908 creator A5080864980 @default.
- W4387472908 creator A5093032276 @default.
- W4387472908 date "2023-10-10" @default.
- W4387472908 modified "2023-10-16" @default.
- W4387472908 title "Novel corticosteroid formulations in the treatment of eosinophilic esophagitis: what is the evidence?" @default.
- W4387472908 doi "https://doi.org/10.51821/86.3.11757" @default.
- W4387472908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37814560" @default.
- W4387472908 hasPublicationYear "2023" @default.
- W4387472908 type Work @default.
- W4387472908 citedByCount "0" @default.
- W4387472908 crossrefType "journal-article" @default.
- W4387472908 hasAuthorship W4387472908A5080864980 @default.
- W4387472908 hasAuthorship W4387472908A5093032276 @default.
- W4387472908 hasConcept C126322002 @default.
- W4387472908 hasConcept C142724271 @default.
- W4387472908 hasConcept C16005928 @default.
- W4387472908 hasConcept C204787440 @default.
- W4387472908 hasConcept C27081682 @default.
- W4387472908 hasConcept C2776042228 @default.
- W4387472908 hasConcept C2776136866 @default.
- W4387472908 hasConcept C2776804153 @default.
- W4387472908 hasConcept C2777819096 @default.
- W4387472908 hasConcept C2779028295 @default.
- W4387472908 hasConcept C2779134260 @default.
- W4387472908 hasConcept C2781065132 @default.
- W4387472908 hasConcept C2781212218 @default.
- W4387472908 hasConcept C535046627 @default.
- W4387472908 hasConcept C71924100 @default.
- W4387472908 hasConcept C90924648 @default.
- W4387472908 hasConceptScore W4387472908C126322002 @default.
- W4387472908 hasConceptScore W4387472908C142724271 @default.
- W4387472908 hasConceptScore W4387472908C16005928 @default.
- W4387472908 hasConceptScore W4387472908C204787440 @default.
- W4387472908 hasConceptScore W4387472908C27081682 @default.
- W4387472908 hasConceptScore W4387472908C2776042228 @default.
- W4387472908 hasConceptScore W4387472908C2776136866 @default.
- W4387472908 hasConceptScore W4387472908C2776804153 @default.
- W4387472908 hasConceptScore W4387472908C2777819096 @default.
- W4387472908 hasConceptScore W4387472908C2779028295 @default.
- W4387472908 hasConceptScore W4387472908C2779134260 @default.
- W4387472908 hasConceptScore W4387472908C2781065132 @default.
- W4387472908 hasConceptScore W4387472908C2781212218 @default.
- W4387472908 hasConceptScore W4387472908C535046627 @default.
- W4387472908 hasConceptScore W4387472908C71924100 @default.
- W4387472908 hasConceptScore W4387472908C90924648 @default.
- W4387472908 hasIssue "3" @default.
- W4387472908 hasLocation W43874729081 @default.
- W4387472908 hasOpenAccess W4387472908 @default.
- W4387472908 hasPrimaryLocation W43874729081 @default.
- W4387472908 hasRelatedWork W1968972903 @default.
- W4387472908 hasRelatedWork W1975221239 @default.
- W4387472908 hasRelatedWork W2020812663 @default.
- W4387472908 hasRelatedWork W2030829101 @default.
- W4387472908 hasRelatedWork W2055935555 @default.
- W4387472908 hasRelatedWork W2094450511 @default.
- W4387472908 hasRelatedWork W2100041918 @default.
- W4387472908 hasRelatedWork W2343833591 @default.
- W4387472908 hasRelatedWork W2983979385 @default.
- W4387472908 hasRelatedWork W2990034293 @default.
- W4387472908 hasVolume "86" @default.
- W4387472908 isParatext "false" @default.
- W4387472908 isRetracted "false" @default.
- W4387472908 workType "article" @default.